Back to Search
Start Over
FibroGen Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2
- Source :
- GlobeNewswire. December 22, 2020
- Publication Year :
- 2020
-
Abstract
- SAN FRANCISCO, Dec 22, 2020 (GLOBE NEWSWIRE via COMTEX) -- FibroGen, Inc. (NASDAQ: FGEN) today announced dosing of the first patient in the ZEPHYRUS-2 Phase 3 clinical study of pamrevlumab [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- GlobeNewswire
- Publication Type :
- News
- Accession number :
- edsgcl.646156571